Filing Details

Accession Number:
0001209191-12-003316
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2012-01-11 17:11:14
Reporting Period:
2011-12-20
Filing Date:
2012-01-11
Filing Date Changed:
2012-01-11
Accepted Time:
2012-01-11 17:11:14
Original Submission Date:
2011-12-22
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235007 Endocyte Inc ECYT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1139814 Lp Fund Investment Co Biomedical V Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1160649 Lp Biomedical V Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1169312 Kg Co & Gmbh Beteiligungs V Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1267960 Partnership Ltd V Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1306695 Lp Fund Investment Co Vi Partners Venture Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1316917 Sanderling Venture Partners V, Lp 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1316918 Sanderling Venture Partners V Co Investment Fund, Lp 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1429282 Partnership Limited Vi Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1429283 Kg Co & Gmbh Beteiligungs Vi Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1512540 Lp Fund Exit Strategic V Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings
Common Stock Acquisiton 2011-12-20 197,800 $3.20 633,661
Common Stock Acquisiton 2011-12-21 197,800 $3.16 831,461
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Sanderling Venture Partners VI Co-Investment Fund, L.P.
No 4 P Indirect By Sanderling Venture VI Co-Investment Fund, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,017,304 Indirect By Sanderling Venture Partners V, L.P.
Common Stock 267,491 Indirect By Sanderling Venture Partners V Co-Investment Fund, L.P.
Common Stock 249,148 Indirect By Sanderling V Biomedical, L.P.
Common Stock 162,170 Indirect By Sanderling V Biomedical Co-Investment Fund, L.P.
Common Stock 113,315 Indirect By Sanderling V Limited Partnership
Common Stock 100,828 Indirect By Sanderling V Beteiligungs GmbH & Co. KG
Common Stock 10,049 Indirect By Sanderling VI Limited Partnership
Common Stock 8,434 Indirect By Sanderling VI Beteiligungs GmbH & Co. KG
Common Stock 785,417 Indirect By Sanderling V Strategic Exit Fund, L.P.
Footnotes
  1. The form 4 is being amended to correct the number of shares acquired which was incorrectly reported in the original filing.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to $3.27, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
  4. Fred Middleton is a managing director of Middleton, McNeil & Mills Associates V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling VI Limited Partnership and Sanderling V Strategic Exit Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling V Strategic Exit Fund, L.P. and Sanderling VI Limited Partnership.
  5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.21, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. Fred Middleton is a managing director of Middleton, McNeil & Mills Associate V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners V Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares of record by Sanderling Venture Partners V Co-Investment Fund, L.P.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!